Chemotherapy management of breast cancer patients according to the clinicopathological characteristics at Dr. Kariadi General Hospital, Semarang 2020-2022

Background: Breast cancer has different histopathological features and can be classified into two, namely invasive and non-invasive breast cancer. Management that can be given to breast cancer patients includes surgery (surgery), chemotherapy, radiation therapy, and hormonal therapy. This study aims to evaluate the chemotherapy management of breast cancer patients according to the clinicopathological characteristics at Dr. Kariadi General Hospital, Semarang 2020-2022. Methods: A cross-sectional study was conducted among 45 patients at Dr. Kariadi General Hospital with a total sampling technique during 2020-2022. Several parameters assessed include age, gender, Body Mass Index (BMI), histopathology characteristics, differentiation grade, stage, immunohistochemistry subtype, and chemotherapy management. Data were analysed using SPSS version 25.0 for Windows. Results: Most of the respondents >50 years age group (44.4%), followed by females (100.0%), obesity type II (48.9%), invasive ductal carcinoma (53.3%), grade 2 differentiation (77.8%), Stage II (A and B) (71.1%), Luminal B-type breast cancer (44.4%), and FAC (44.4%) as chemotherapy management. Pacli-Doxo was the predominant chemotherapy management in the invasive ductal carcinoma (24.4%) and Luminal B subtypes (31.1%) of breast cancer, followed by FAC chemotherapy in grade 2 (31.1%) and stage II (A and B) (24.4%). Conclusion: Pacli-Doxo was the predominant chemotherapy management in the invasive ductal carcinoma and Luminal B subtypes of breast cancer, followed by FAC chemotherapy in grade 2 and stage II (A and B).